At Thompson’s we would like to reassure all our clients that as far as possible we are operating as normal. The health and safety of our staff and clients is our primary concern during this outbreak and as such we are reviewing the situation on a regular basis and will be adapting our working practices following government guidelines. However, we have had to make some minor changes to how we are doing things.

Following Government guidelines, we have temporarily closed all of our offices and our staff are now all working from home using secure technologies to ensure they are able to continue to progress with existing and new cases as normal. All face to face meetings have been cancelled, however we are continuing to hold these meetings via phone and video calls. All the team are contactable on their direct dial numbers and email should you need to speak with your solicitor, please do not hesitate to talk to us about anything during this time.

We know these are uncertain and unsettling times for many of our clients, and the wider population, and things might look a little different for the foreseeable future. But our focus remains on our dedication, knowledge and strength that we provide to all our clients. We will continue to provide updates over the coming days and weeks in accordance with official guidelines and to keep everyone informed of the situation.

As always, for any concerns, advice and updates on your case; Talk to Thompsons.

Click Here to Visit our Covid 19 Information Hub

Click Here to Read More About Covid 19 & Thompsons

Thompsons Solicitors Scotland
Thompsons Solicitors Scotland

The NHS have recently agreed to fund a new drug which aims to treat severe asthma.  The injection of Benralizumab, which costs almost £2,000 per dose, will be used for those suffering from eosinophilic asthma. Following approval for NHS by NICE (the National Institute for Health and Care Excellence) the drug will be given to patients as an injection once every four weeks for three months and once every eight weeks thereafter.

The introduction of this medication has been welcomed by charities such as Asthma UK, as a means to reduce the risk of asthma attacks in those suffering from eosinophilic asthma which often does not respond well to traditional treatment, such as inhalers.  Eosonphilic asthma is caused by increased white blood cells in the lungs and this new drug is designed to stop the body producing these.

Although it is not yet clear whether the drug will be available in Scotland, this is a huge step forward by those suffering from asthma. Eosinophilic asthma is a unique form of the condition, as it affects only 1.3 percent of the 5.4 million people living with the disease, and therefore continued development in the treatment of asthma in general is necessary. Although asthma is a common condition, it is incurable and the symptoms of it cannot be overstated – recent data has shown that deaths from asthma in the UK have risen by a quarter in the past five years. 

We at Thompsons regularly deal with compensation claims on behalf of workers who have developed industrial asthma through their exposure to harmful dust or fumes at work.   Occupational exposure is one of the single largest causes of the onset of asthma in adults and this can be triggered by exposure to many substances including wood dust, flour and grain, cleaning products, paint and glue – the list is almost endless. Many of our clients have to stop work or change  their career due to their asthma and so further research and development into treatment of the condition is vital, particularly from the NHS in Scotland. 

If you suffer from asthma and consider this condition has been caused or contributed to by exposure to harmful substances at work, then Talk to Thompsons.

Blog by Claire Campbell, Solicitor

Claim Now